RxDoctor Payments Data

Kenzie Smith, MD

Family Medicine · Brentwood, TNNPI 1609225911

Payments from drug & device makers

$8,320in general payments, 2019–2025

Across 436 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$857
  • Lilly USA, LLC$811
  • Amgen$581
  • GSK$532
  • Biohaven Pharmaceuticals, Inc.$452
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$8,22099%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,320 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$100,161
Medicare patients
184
Services billed
2,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$104,074
EliquisApixaban30$44,349
MounjaroTirzepatide30$32,528
JardianceEmpagliflozin19$19,602
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,364
FarxigaDapagliflozin Propanediol11$8,972
Potassium Chloride25$4,738
SynthroidLevothyroxine Sodium25$2,982
PaxlovidNirmatrelvir/Ritonavir13$2,764
Atorvastatin Calcium219$2,762
Rosuvastatin Calcium188$2,377
Ezetimibe62$1,483
Trazodone Hcl71$1,423
Amlodipine-ValsartanAmlodipine Besylate/Valsartan12$1,338
Levothyroxine Sodium148$1,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,419$104,07472 claims
PfizerEliquis, Paxlovid$432$47,11343 claims
Lilly USA, LLCMounjaro$811$32,52830 claims
Boehringer IngelheimJardiance$128$19,60219 claims
GSKTrelegy Ellipta$532$14,36415 claims
AstraZenecaFarxiga$377$8,97211 claims
AbbVieSynthroid$857$2,98225 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$27$1,288148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Brentwood

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →